# Vir Biotechnology, Inc. Common Stock (VIR)

> Vir Biotechnology, Inc. Common Stock (VIR) trades at $13.15 (-3.63%) as of 7:55:50 PM EST on Nov 10, 2026, +16.37% over the past month. Market cap is $2.34B, with 11.9 days to cover in short interest.

Canonical: https://massive.com/quote/vir
Data as of: 2026-11-11T00:55:50.510Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$13.15** -0.49 (-3.63%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$13.05** -0.10 (-0.76%)
As of 7:55:50 PM EST on Nov 10, 2026 · After hours

## Stock performance

How Vir Biotechnology, Inc. Common Stock (VIR) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -3.63% |
| 1W | +17.20% |
| 1M | +16.37% |
| YTD | +118.08% |
| 1Y | +130.30% |
| 52-wk range | $5.32 – $14.38 |

From daily closes through Nov 10, 2026.

## Key statistics

Today's trading snapshot for VIR: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $13.11 – $13.74 |
| Open | $13.66 |
| Prev close | $13.65 |
| Volume | 1.3M |
| Market cap | $2.34B |
| Shares out | 171.27M |

## Valuation and profitability ratios

Valuation and profitability ratios for Vir Biotechnology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 7.72 |
| P/B | 2.61 |
| P/FCF | — |
| ROE | -20.6% |
| ROA | -16.6% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 9, 2026

## Insider trading

[Vir Biotechnology, Inc. Common Stock (VIR) insider trading](https://massive.com/quote/vir/insider-trading.md): open-market Form 4 buys and sells by Vir Biotechnology, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Vir Biotechnology, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Additional Week 96 data from the Phase 2 SOLSTICE trial show that treatment with elebsiran and tobevibart drove rapid HDV RNA suppression, with 100% (28/28) of patients who completed Week 96 of combination therapy reaching undetectable viremia. Among patients with paired liver stiffness measurements, 89% (24/27) had improved or stable liver stiffness at Week 96.”
- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Oct 28, 2026 · Director appointment
  “On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) ... approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders ... effective as of October 27, 2026.”
- Oct 14, 2026 · Partnership or collaboration
  “On October 9, 2026, Vir Biotechnology, Inc. (Vir Bio) and Gilead Sciences, Inc. (Gilead) entered into a Collaboration and License Agreement (the Agreement), pursuant to which Vir Bio and Gilead will enter into a global strategic collaboration to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens.”
- Oct 8, 2026 · Partnership or collaboration
  “VIR-5500 is being co-developed by Astellas Pharma Inc. and the Company through a global strategic collaboration.”

## VIR short interest

How heavily VIR is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 11.9 |
| Short interest | 16.87M |
| Avg volume | 1.42M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## VIR news

The latest news and headlines about Vir Biotechnology, Inc. Common Stock (VIR).

- [Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know](https://www.zacks.com/stock/news/3026471/wall-street-analysts-predict-a-75-59-upside-in-vir-biotechnology-vir-here-s-what-you-should-know?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3026471) · Zacks Investment Research · Nov 9, 2026 · positive sentiment
- [Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?](https://www.zacks.com/stock/news/3017925/beam-therapeutics-beam-moves-15-6-higher-will-this-strength-last?cid=CS-ZC-FT-fundamental_analysis|daily_price_change_5%-3017925) · Zacks Investment Research · Oct 29, 2026 · positive sentiment
- [Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?](https://www.zacks.com/stock/news/3008864/can-gilead-s-deal-with-vir-boost-its-oncology-pipeline-and-growth?cid=CS-ZC-FT-analyst_blog|quick_take-3008864) · Zacks Investment Research · Oct 15, 2026 · neutral sentiment
- [Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally](https://www.fool.com/coverage/filings/2026/05/23/why-a-biotech-fund-opened-a-new-usd6-million-position-in-vir-amid-a-99-stock-rally/?source=iedfolrf0000001) · The Motley Fool · May 23, 2026 · positive sentiment
- ["Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies](https://www.globenewswire.com/news-release/2026/05/14/3295171/0/en/Cold-Solid-Tumors-Become-the-Proving-Ground-for-a-New-Generation-of-Engager-and-Immune-Priming-Therapies.html) · GlobeNewswire Inc. · May 14, 2026 · positive sentiment

## About Vir Biotechnology, Inc. Common Stock

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 367 |
| Listed | Oct 11, 2019 |

[Company website](https://www.vir.bio)

## FAQ

### What is the Vir Biotechnology, Inc. Common Stock (VIR) stock price today?

Vir Biotechnology, Inc. Common Stock (VIR) is trading at $13.15 (-3.63% on the day) as of 7:55:50 PM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Vir Biotechnology, Inc. Common Stock?

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer.

### What is the short interest in VIR?

As of Oct 30, 2026, VIR has 16.87M shares short and 11.9 days to cover.

### What exchange is VIR listed on?

Vir Biotechnology, Inc. Common Stock (VIR) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time VIR quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=VIR`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Vir Biotechnology, Inc. Common Stock (VIR) insider trading](https://massive.com/quote/vir/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
